The role of nutrition and nutraceutical supplements in the prevention and treatment of hypertension

Clinical Practice

Volumn 10, Issue 2, 2013, Pages 209-229

  Houston, Mark C ^a  

^a Hypertension Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ARGININE; ASCORBIC ACID; CAPTOPRIL; CARNITINE; DOCOSAHEXAENOIC ACID; FLAVONOID; GARLIC EXTRACT; ICOSAPENTAENOIC ACID; LYCOPENE; MELATONIN; OLIVE LEAF EXTRACT; OLIVE OIL; OMEGA 3 FATTY ACID; OMEGA 9 FATTY ACID; PLACEBO; PLANT EXTRACT; PYCNOGENOL; PYRIDOXINE; S ALLYLCYSTEINE; SESAMIN; SUNFLOWER OIL; TAURINE; THIOCTIC ACID; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNSATURATED FATTY ACID; VITAMIN D;

AUTOIMMUNE DISEASE; CACAO; CALCIUM INTAKE; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIET SUPPLEMENTATION; ELECTROLYTE INTAKE; ESSENTIAL HYPERTENSION; EVENING DOSAGE; FAT INTAKE; FOOD DRUG INTERACTION; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HIGH FIBER DIET; HIGH MAGNESIUM INTAKE; HIGH POTASSIUM INTAKE; HUMAN; HYPERLIPIDEMIA; IMMUNOPATHOGENESIS; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN DIET; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SEAWEED; SESAME; SODIUM RESTRICTION; TEA; ZINC INTAKE;

EID: 84874629753     PISSN: 20449038     EISSN: 20449046     Source Type: Journal    
DOI: 10.2217/cpr.13.2     Document Type: Review

References (256)

1. Houston MC. Treatment of hypertension with nutraceuticals. Vitamins, antioxidants and minerals. Expert Rev. Cardiovasc. Ther. 5(4), 681-691 (2007)
2. Eaton SB, Eaton SB 3rd, Konner MJ. Paleolithic nutrition revisited: a twelve-year retrospective on its nature and implications. Eur. J. Clin. Nutr. 51, 207-216 (1997)
3. Layne J, Majkova Z, Smart EJ, Toborek M, Hennig B. Caveolae: a regulatory platform for nutritional modulation of inflammatory diseases. J. Nutr. Biochem. 22, 807-811 (2011)
4. Dandona P, Ghanim H, Chaudhuri A, Dhindsa S, Kim SS. Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. Exp. Mol. Med. 42(4), 245-253 (2010)
5. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC-7). JAMA 289, 2560-2572 (2003)
6. Kizhakekuttu TJ, Widlansky ME. Natural antioxidants and hypertension: promise and challenges. Cardiovasc. Ther. 28(4), e20-e32 (2010)
7. Houston MC. New insights and approaches to reduce end organ damage in the treatment of hypertension: subsets of hypertension approach. Am. Heart J. 123, 1337-1367 (1992)
8. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in six European countries, Canada and the United States. JAMA 289, 2363-2369 (2003)
9. Nayak DU, Karmen C, Frishman WH, Vakili BA. Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers in the prevention and treatment of cardiovascular disease. Heart Dis. 3, 28-45 (2001)
10. Kitiyakara C, Wilcox C. Antioxidants for hypertension. Curr. Opin Nephrol. Hypertens. 7, 531-538 (1998)
11. Russo C, Olivieri O, Girelli D et al. Antioxidant status and lipid peroxidation in patients with essential hypertension. J. Hypertens. 16, 1267-1271 (1998)
12. Tse WY, Maxwell SR, Thomason H et al. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J. Hum. Hypertens. 8, 843-849 (1994)
13. Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clin. Sci. 92, 361-365 (1997)
14. Dhalla NS, Temsah RM, Netticadam T. The role of oxidative stress in cardiovascular diseases. J. Hypertens. 18, 655-673 (2000)
15. Saez G, Tormos MC, Giner V, Lorano JV, Chaves FJ. Oxidative stress and enzymatic antioxidant mechanisms in essential hypertension. Am. J. Hypertens. 14, 248A (2001) (Abstract P-653)
16. Ghanem FA, Movahed A. Inflammation in high blood pressure: a clinician perspective. J. Am. Soc. Hypertens. 1(2), 113-119 (2007)
17. Amer MS, Elawam AE, Khater MS, Omar OH, Mabrouk RA, Taha HM. Association of high-sensitivity C reactive protein with carotid artery intima media thickness in hypertensive older adults. J. Am. Soc. Hypertens. 5(5), 395-400 (2011)
18. Kvakan H, Luft FC, Muller DN. Role of the immune system in hypertensive target organ damage. Trends Cardiovasc. Med. 19(7), 242-246 (2009)
19. Rodriquez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ. Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin. Exp. Pharmacol. Physiol. 39(1), 96-103 (2012)
20. Mansego ML, Solar Gde M, Alonso MP et al. Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J. Hypertens. 29(3), 492-500 (2011)
21. Vongpatanasin W, Thomas GD, Schwartz R et al. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation 115(8), 1020-1028 (2007)
22. Razzouk L, Munter P, Bansilal S et al. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am. Heart J. 158(2), 277-283 (2009)
23. Tian N, Penman AD, Mawson AR, Manning RD Jr, Flessner MF. Association between circulating specific leukocyte types and blood pressure. The Atherosclerosis risk in communities (ARIC) study. J. Am. Soc. Hypertens. 4(6), 272-283 (2010)
24. Muller DN, Kvakan H, Luft FC. Immune-related effects in hypertension and target-organ damage. Curr. Opin Nephrol. Hypertens. 20(2), 113-117 (2011)
25. Leibowitz A, Schiffin EL. Immune mechanisms in hypertension. Curr. Hypertens. Rep 13(6), 465-472 (2011)
26. Berdanier CD. Nutrient-gene interactions. In: Present Knowledge in Nutrition (7th Edition). Ziegler EE, Filer LJ Jr (Eds). ILSI Press, Washington DC, USA, 574-580 (1996)
27. Talmud PJ, Waterworth DM. In vivo and in vitro nutrient-gene interactions. Curr. Opin Lipidol. 11, 31-36 (2000)
28. Houston MC. The importance of potassium in managing hypertension. Curr. Hypertens. Rep. 13(4), 309-317 (2011)
29. Broadhurst CL. Balanced intakes of natural triglycerides for optimum nutrition: an evolutionary and phytochemical perspective. Med. Hypotheses 49, 247-261 (1997)
30. Kotchen TA, McCarron DA. AHA science advisory. Dietary electrolytes and blood pressure. Circulation 98, 613-617 (1998)
31. Cutler JA, Follmann, Allender PS. Randomized trials of sodium reduction: an overview. Am. J. Clin. Nutr. 65, S643-S651 (1997)
32. Svetkey LP, Sacks FM, Obarzanek E et al. The DASH diet, sodium intake and blood pressure (the DASH-Sodium Study): rationale and design. JADA 99, S96-S104 (1999)
33. Messerli FH, Schmieder RE, Weir MR. Salt: a perpetrator of hypertensive target organ disease? Arch. Intern. Med. 157, 2449-2452 (1997)
34. Kawasaki T, Delea CS, Bartter FC, Smith H. The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension. Am. J. Med. 64, 193-198 (1978)
35. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 27, 481-490 (1996)
36. Morimoto A, Usu T, Fujii T et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350, 1734-1737 (1997)
37. Houston MC. Nutraceuticals, vitamins, antioxidants and mineral in the prevention and treatment of hypertension. Prog. Cardiovasc. Dis 47(6), 396-449 (2005)
38. Houston MC. Nutrition and nutraceutical supplements in the treatment of hypertension. Expert Rev. Cardiovasc. Ther. 8(6), 821-833 (2010)
39. Kanbay M, Chen Y, Solak Y, Sanders PW. Mechanisms and consequences of salt sensitivity and dietary salt intake. Curr. Opin Nephrol. Hypertens. 20(1), 37-43 (2011)
40. Oberleithner H, Callies C, Kusche-Vihrog K et al. Potassium softens vascular endothelium and increases nitric oxide release. Proc. Natl Acad. Sci. USA 106(8), 2829-2834 (2009)
41. Feis J, Oberleithner H, Kusche-Vihrog K. Menage a trios: aldosteron, sodium and nitric oxide in vascular endothelium. Biochim. Biophys. Acta 1802(12), 1193-1202 (2010)
42. Toda N, Arakawa K. Salt-induced hemodynamic regulation mediated by nitric oxide. J. Hypertens. 29(3), 415-424 (2011)
43. Foulquier S, Dupuis F, Perrin-Sarrado C et al. High salt intake abolishes AT(2)-mediated vasodilation of pial arterioes in rats. J. Hypertens. 29(7), 1392-1399 (2011)
44. Yang Q, Liu T, Kuklina EV et al. Sodium and potassium intake and mortality among US adults: prospective data from the Third National Health and Nutrition Examination Survey. Arch. Int. Med. 171(13), 1183-1191 (2011)
45. Houston MC, Harper KJ. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J. Clin. Hypertens. 10 (7 Suppl. 2), 3-11 (2008)
46. Whelton PK, He J. Potassium in preventing and treating high blood pressure. Semin. Nephrol. 19, 494-499 (1999)
47. Gu D, He J, Xigui W, Duan X, Whelton PK. Effect of potassium supplementation on blood pressure in Chinese: a randomized, placebo-controlled trial. J. Hypertens. 19, 1325-1331 (2001)
48. Widman L, Wester PO, Stegmayr BG, Wirell MP. The dose dependent reduction in blood pressure through administration of magnesium: a double blind placebo controlled cross-over trial. Am. J. Hypertens. 6, 41-45 (1993)
49. Laurant P, Touyz RM. Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension. J. Hypertens. 18, 1177-1191 (2000)
50. Houston MC. The role of magnesium in hypertension and cardiovascular disease. J. Clin. Hypertens. 13(11), 843-847 (2011)
51. McCarron DA. Role of adequate dietary calcium intake in the prevention and management of salt sensitive hypertensive. Am. J. Clin. Nutr. 65, S712-S716 (1997)
52. Resnick LM. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care 14, 505-520 (1991)
53. Garcia Zozaya JL, Padilla Viloria M. Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the rennin-angiotensin- aldosterone system. Invest. Clin. 38, 27-40 (1997)
54. Bergomi M, Rovesti S, Vinceti M, Vivoli R, Caselgrandi E, Vivoli G. Zinc and copper status and blood pressure. J. Trace Elem. Med. Biol. 11, 166-169 (1997)
55. Shahbaz AU, Sun Y, Bhattacharya SK et al. Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies. J. Hypetens. 28, S25-S32 (2010)
56. Stamler J, Elliott P, Kesteloot H et al. Inverse relation of dietary protein markers with blood pressure. Findings for 10,020 men and women in the Intersalt Study. Intersalt Cooperative Research Group. International study of salt and blood pressure. Circulation 94, 1629-1634 (1996)
57. Altorf-van der Kuil W, Engberink MF, Brink EJ et al. Dietary protein and blood pressure: a systematic review. PLoS ONE 5(8), e12102-e12117 (2010)
58. Jenkins DJ, Kendall CW, Faulkner DA et al. Long-term effects of a plant-based dietary portfolio of cholesterol-lowering foods on blood pressure. Eur. J. Clin. Nutr. 62(6), 781-788 (2008)
59. Elliott P, Dennis B, Dyer AR et al. Relation of dietary protein (total, vegetable, animal) to blood pressure: INTERMAP epidemiologic study. Presented at: The 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL, USA, 20-24 August 2000
60. He J, Wofford MR, Reynolds K et al. Effect of dietary protein supplementation on blood pressure: a randomized controlled trial. Circulation 124(5), 589-595 (2011)
61. FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. J. Nutr. 134(4), S980-S988 (2004)
62. Pins JJ, Keenan JM. Effects of whey peptides on cardiovascular disease risk factors. J. Clin. Hypertens. 8(11), 775-782 (2006)
63. Aihara K, Kajimoto O, Takahashi R, Nakamura Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J. Am. Coll. Nutr. 24(4), 257-265 (2005)
64. Gemino FW, Neutel J, Nonaka M, Hendler SS. The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives. J. Clin. Hypertens. 12(3), 153-159 (2010)
65. Geleijnse JM, Engberink MF. Lactopeptides and human blood pressure. Curr. Opin Lipidol. 21(1), 58-63 (2010)
66. Pins J, Keenan J. The antihypertensive effects of a hydrolyzed whey protein supplement. Cardiovasc. Drugs Ther. 16(Suppl.), 68 (2002)
67. Zhu CF, Li GZ, Peng HB, Zhang F, Chen Y, Li Y. Therapeutic effects of marine collagen peptides on Chinese patients with Type 2 diabetes mellitus and primary hypertension. Am. J. Med. Sci. 340(5), 360-366 (2010)
68. De Leo F, Panarese S, Gallerani R, Ceci LR. Angiotensin converting enzyme (ACE) inhibitoroy peptides: production and implementation of functional food. Curr. Pharm. Des. 15(31), 3622-3643 (2009)
69. Lordan S, Ross P, Stanton C. Marine bioactives as functional food ingredients: potential to reduce the incidence of chronic disease. Mar. Drugs 9(6), 1056-1100 (2011)
70. Kawasaki T, Seki E, Osajima K et al. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. J. Hum. Hypertens. 14, 519-523 (2000)
71. Kawasaki T, Jun CJ, Fukushima Y, Seki E. [Antihypertensive effect and safety evaluation of vegetable drink with peptides derived from sardine protein hydrolysates on mild hypertensive, high-normal and normal blood pressure subjects]. Fukuoka Igaku Zasshi 93(10), 208-218 (2002)
72. Yang G, Shu XO, Jin F et al. Longitudinal study of soy food intake and blood pressure among middle-aged and elderly Chinese women. Am. J. Clin. Nutr. 81(5), 1012-1017 (2005)
73. Teede HJ, Giannopoulos D, Dalais FS, Hodgson J, McGrath BP. Randomised, controlled, cross-over trial of soy protein with isoflavones on blood pressure and arterial function in hypertensive patients. J. Am. Coll. Nutr. 25(6), 533-540 (2006)
74. Welty FK, Lee KS, Lew NS, Zhou JR. Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive and normotensive postmenopausal women. Arch. Intern. Med. 167(10), 1060-1067 (2007)
75. Rosero Arenas MA, Roser Arenas E, Portaceli Arminana MA, Garcia Garcia MA. Usefulness of phyto-oestrogens in reduction of blood pressure. Systematic review and meta-analysis. Aten. Primaria 40(4), 177-186 (2008)
76. Nasca MM, Zhou JR, Welty FK. Effect of soy nuts on adhesion molecules and markers of inflammation in hypertensive and normotensive postmenopausal women. Am. J. Cardiol. 102(1), 84-86 (2008)
77. He J, Gu D, Wu X et al. Effect of soybean protein on blood pressure: a randomized, controlled trial. Ann. Intern. Med. 143(1), 1-9 (2005)
78. Hasler CM, Kundrat S, Wool D. Functional foods and cardiovascular disease. Curr. Atheroscler. Rep. 2(6), 467-475 (2000)
79. Tikkanen MJ, Adlercreutz H. Dietary soy-derived isoflavone phytoestrogens. Could they have a role in coronary heart disease prevention? Biochem. Pharmacol. 60(1), 1-5 (2000)
80. Begg DP, Sinclari AJ, Stahl LA, Garg ML, Jois M, Weisinger RS. Dietary proteins level interacts with omega-3 polyunsaturated fatty acid deficiency to induce hypertension. Am. J. Hypertens. 23(2), 125-128 (2009)
81. Morris MC. Dietary fats and blood pressure. J. Cardiovasc. Risk 1, 21-30 (1994)
82. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34, 253-260 (1999)
83. Bønaa KH, Bjerve KS, Straume B, Gram IT, Thelle D. Effect of eicosapentaenoic and docosahexanoic acids on blood pressure in hypertension: a population-based intervention trial from the Tromso study. N. Engl. J. Med. 322, 795-801 (1990)
84. Mori TA, Burke V, Puddey I, Irish A. The effects of omega 3 fatty acids and coenzyme q 10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J. Hypertens. 27(9), 1863-1872 (2009)
85. Ueshima H, Stamler J, Elliot B, Brown CQ. Food omega 3 fatty acid intake of individuals (total, linolenic acid, long chain) and their blood pressure: INTERMAP study. Hypertension 50(20), 313-319 (2007)
86. Mon TA. Omega3 fatty acids and hypertension in humans. Clin. Exp. Pharmacol. Physiol. 33(9), 842-846 (2006)
87. Liu JC, Conkin SM, Manuch SB, Yao JK, Muldoon MF. Long-chain omega-3 fatty acids and blood pressure. Am. J. Hypertens 24(10), 1121-1126 (2011)
88. Engler MM, Schambelan M, Engler MB, Goodfriend TL. Effects of dietary gamma-linolenic acid on blood pressure and adrenal angiotensin receptors in hypertensive rats. Proc. Soc. Exp. Biol. Med. 218(3), 234-237 (1998)
89. Sagara M, Njelekela M, Teramoto T et al. Effects of docozhexaenoic acid supplementation on blood pressure, heart rate, and serum lipid in Scottish men with hypertension and hypercholesterolemia. Int. J. Hypertens. 8, 8091-8098 (2011)
90. Chin JP. Marine oils and cardiovascular reactivity. Prostaglandins Leukot. Essent. Fatty Acids 50, 211-222 (1994)
91. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 376(9740), 540-550 (2010)
92. Ferrara LA, Raimondi S, d'Episcopa I. Olive oil and reduced need for antihypertensive medications. Arch. Intern. Med. 160, 837-842 (2000)
93. Thomsen C, Rasmussen OW, Hansen KW, Vesterlund M, Hermansen K. Comparison of the effects on the diurnal blood pressure, glucose, and lipid levels of a diet rich in monounsaturated fatty acids with a diet rich in polyunsaturated fatty acids in Type 2 diabetic subjects. Diabet. Med. 12, 600-606 (1995)
94. Perona JS, Canizares J, Montero E, Sanchez-Dominquez JM, Catala A, Ruiz-Gutierrez V. Virgin olive oil reduces blood pressure in hypertensive elderly patients. Clin. Nutr. 23(5), 1113-1121 (2004)
95. Perona JS, Montero E, Sanchez-Dominquez JM, Canizares J, Garcia M, Ruiz-Gutierrez V. Evaluation of the effect of dietary virgin olive oil on blood pressure and lipid composition of serum and low-density lipoprotein in elderly type 2 subjects. J. Agric. Food Chem. 57(23), 11427-11433 (2009)
96. Lopez-Miranda J, Perez-Jimenez F, Ros E et al. Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008. Nutr. Metab. Cardiovasc. Dis 20(4), 284-294 (2010)
97. Susalit E, Agus N, Effendi K et al. Olive (Olea europaea)leaf extract effective is patients with stage-1 hypertension: comparison with captopril. Phytomedicine 18(4), 251-258 (2011)
98. He J, Whelton PK. Effect of dietary fiber and protein intake on blood pressure: a review of epidemiologic evidence. Clin. Exp. Hypertens. 21, 785-796 (1999)
99. Pruijm M, Wuerzer G, Forni V, Bochud M, Pechere-Bertschi A, Burnier M. Nutrition and hypertension: more than table salt. Rev. Med. Suisse 6(282), 1715-1720 (2010)
100. Simons S, Wollersheim H, Thien T. A systematic review on the influence of trial quality on the effects of garlic on blood pressure. Neth. J. Med. 67(6), 212-219 (2009)
101. Reinhard KM, Coleman CI, Teevan C, Vacchani P. Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. Ann. Pharmacother. 42(12), 1766-1771 (2008)
102. Reid K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomized controlled trial. Maturitas 67(2), 144-150 (2010)
103. Hodgson JM, Puddey IB, Burke V, Beilin LJ, Jordan N. Effects on blood pressure of drinking green and black tea. J. Hypertens. 17, 457-463 (1999)
104. Wahabi HA, Alansary LA, Al-Sabban AH, Glasziuo P. The effectiveness of Hibiscus Sabdariffa in the treatment of hypertension: a systematic review. Phytomedicine 17(2), 83-86 (2010)
105. Kurita I, Maeda-Yamamoto M, Tachibana H, Kamei M. Anti-hypertensive effect of Benifuuki tea containing O-methylated EGCG. J. Agric. Food Chem. 58(3), 1903-1908 (2010)
106. McKay DL, Chen CY, Saltzman E, Blumberg JB. Hibiscus sabdariffa L tea (tisane) lowers blood pressure in pre-hypertensive and mildly hypertensive adults. J. Nutr. 140(2), 298-303 (2010)
107. Nakano T, Hidaka H, Uchida J, Nakajima K, Hata Y. Hypotensive effects of wakame. J. Jpn Soc. Clin. Nutr. 20, 92 (1998)
108. Krotkiewski M, Aurell M, Holm G, Grimby G, Szckepanik J. Effects of a sodium-potassium ion-exchanging seaweed preparation in mild hypertension. Am. J. Hypertens. 4, 483-488 (1991)
109. Suetsuna K, Nakano T. Identification of an antihypertensive peptide from peptic digest of wakame (Undaria pinnatifida). J. Nutr. Biochem. 11, 450-454 (2000)
110. Sato M, Oba T, Yamaguchi T et al. Antihypertensive effects of hydrolysates of wakame (Undaria pinnatifida) and their angiotnesin-1-converting inhibitory activity. Ann. Nutr. Metab. 46(6), 259-267 (2002)
111. Sato M, Hosokawa T, Yamaguchi T et al. Angiotensin I converting enzymeinhibitory peptide derived from wakame (Undaria pinnatifida) and their antihypertensive effect in spontaneously hypertensive rats. J. Agric. Food Chem. 50(21), 6245-6252 (2002)
112. Sherman DL, Keaney JF, Biegelsen ES et al. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 35, 936-941 (2000)
113. Ness AR, Khaw KT, Bingham S, Day NE. Vitamin C status and blood pressure. J. Hypertens. 14, 503-508 (1996)
114. Duffy SJ, Bokce N, Holbrook. Treatment of hypertension with ascorbic acid. Lancet 354, 2048-2049 (1999)
115. Enstrom JE, Kanim LE, Klein M. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 3, 194-202 (1992)
116. Block G, Jensen CD, Norkus EP, Hudes M, Crawford PB. Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young black and white women. Nutr. J. 17(7), 35-46 (2008)
117. Hatzitolios A, Iliadis F, Katsiki N, Baltatzi M. Is the antihypertensive effect of dietary supplements via aldehydes reduction evidence based? A systematic review. Clin. Exp. Hypertens. 30(7), 628-639 (2008)
118. Mahajan AS, Babbar R, Kansai N, Agarwai SK, Ray PC. Antihypertensive and antioxidant action of amlodipine and vitamin C in patients of essential hypertension. J. Clin. Biochem. Nutr. 40(2), 141-147 (2007)
119. Ledlerc PC, Proulx CD, Arquin G, Belanger S. Ascorbic acid decreases the binding affinity of the AT! Receptor for angiotensin II. Am. J. Hypertens. 21(1), 67-71 (2008)
120. Plantinga Y, Ghiadone L, Magagna A, Biannarelli C. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am. J. Hypertens. 20(4), 392-397 (2007)
121. Sato K, Dohi Y, Kojima M, Miyagawa K. Effects of ascorbic acid on ambulatory blood pressure in elderly patients with refractory hypertension. Arzneimittelforschung 56(7), 535-540 (2006)
122. Block G, Mangels AR, Norkus EP, Patterson BH, Levander OA, Taylor PR. Ascorbic acid status and subsequent diastolic and systolic blood pressure. Hypertension 37, 261-267 (2001)
123. McRae MP. Is vitamin C an effective antihypertensive supplement? A review and analysis of the literature. J. Chiropr. Med. 5(2), 60-64 (2006)
124. Simon JA. Vitamin C and cardiovascular disease: a review. J. Am. Coll. Nutr. 11(2), 107-125 (1992)
125. Ness AR, Chee D, Elliott P. Vitamin C and blood pressure-an overview. J. Hum. Hypertens. 11(6), 343-350 (1997)
126. Trout DL. Vitamin C and cardiovascular risk factors. Am. J. Clin. Nutr. 53(Suppl. 1), S322-S325 (1991)
127. National Center for Health Statistics; Fulwood R, Johnson CL et al. Hematological and nutritional biochemistry reference data for persons 6 months-74 years of age: United States, 1976-80. Vital and Health Statistics Series 11, No. 232, DHHS Pub. No. 83-1682 (1982)
128. Ward NC, Wu JH, Clarke MW, Buddy IB. Vitamin E effects on the treatment of hypertension in Type 2 diabetics. J. Hypertens. 227, 227-234 (2007)
129. Murray ED, Wechter WJ, Kantoci D et al. Endogenous natriuretic factors 7: biospecificity of a natriuetic gamma-tocopherol metabolite LLU alpha. J. Pharmacol. Exp. Ther. 282(2), 657-662 (1997)
130. Gray B, Swick J, Ronnenberg AG. Vitamin E and adiponectin: proposed mechanism for vitamin E-induced improvement in insulin sensitivity. Nutr. Rev. 69(3), 155-161 (2011)
131. Hanni LL, Huarfner LH, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens. 8, 894-901 (1995)
132. Bednarski R, Donderski R, Manitius L. [Role of vitamin D in arterial blood pressure control]. Pol. Merkur. Lekarski 136, 307-310 (2007)
133. Li YC, Kong H, Wei M, Chen ZF. 1,25 dihydroxyvitamin D 3 is a negative endocrine regulator of the renin angiotensin system. J. Clin. Invest. 110(2), 229-238 (2002)
134. Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD. Does vitamin D modulate asymmetric dimethylargine and C-reactive protein concentrations? Am. J. Med. 123(4), 335-341 (2010)
135. Rosen CJ. Clinical practice. Vitamin D insufficiency. N. Engl. J. Med. 364(3), 248-254 (2011)
136. Boldo A, Campbell P, Luthra P, White WB. Should the concentration of vitamin D be measured in all patients with hypertension? J. Clin. Hypertens. 12(3), 149-152 (2010)
137. Pittas AG, Chung M, Trikalinos T et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 152(5), 307-314 (2010)
138. Movano Peregrin C, Lopez Rodriguez R, Castilla Castellano MD. [Vitamin D and hypertension]. Med. Clin. (Barc.) 138(9),397-401 (2011)
139. Motiwala SR, Want TJ. Vitamin D and cardiovascular disease. Curr. Opin Nephrol. Hypertens. 20(4), 345-353 (2011)
140. Cosenso-Martin LN, Vitela-Martin JF. Is there an association between vitamin D and hypertension? Recent Pat. Cardiovasc. Drug Discov. 6(2), 140-147 (2011)
141. Bhandari SK, Pashayan S, Liu IL et al. 25-hydroxyvitamin D levels and hypertension rates. J. Clin. Hypertens. 13(3), 170-177 (2011)
142. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 86, 1633-1637 (2001)
143. Keniston R, Enriquez JI Sr. Relationship between blood pressure and plasma vitamin B6 levels in healthy middle-aged adults. Ann. NY Acad. Sci. 585, 499-501 (1990)
144. Aybak M, Sermet A, Ayyildiz MO, Karakilcik AZ. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung 45, 1271-1273 (1995)
145. Paulose CS, Dakshinamurti K, Packer S, Stephens NL. Sympathetic stimulation and hypertension in the pyridoxine-deficient adult rat. Hypertension 11(4), 387-391 (1988)
146. Dakshinamurti K, Lal KJ, Ganguly PK. Hypertension, calcium channel and pyridoxine(vitamin B 6). Mol. Cell. Biochem. 188(1-2), 137-148 (1998)
147. Moline J, Bukharovich IF, Wolff MS, Phillips R. Dietary flavonoids and hypertension: is there a link? Med. Hypotheses 55, 306-309 (2000)
148. Knekt P, Reunanen A, Järvinen R, Seppänen R, Heliövaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am. J. Epidemiol. 139, 1180-1189 (1994)
149. Karatzi KN, Papamichael CM, Karatizis EN et al. Red wine acutely induces favorable effects on wave reflections and central pressures in coronary artery disease patients. Am. J. Hypertens. 18(9), 1161-1167 (2005)
150. Biala A, Tauriainen E, Siltanen A et al. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Press. 19(3), 196-205 (2010)
151. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz L, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis 21(11), 851-856 (2011).
152. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur. J. Pharmacol. 667(1-3), 258-264 (2011)
153. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 77(6), 1053-1063 (2009)
154. Paran E, Engelhard YN. Effect of lycopene, an oral natural antioxidant on blood pressure. J. Hypertens. 19, S74 (2001)
155. Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double blind placebo controlled pilot study. Am. Heart J. 151(1), 100 (2006)
156. Paran E, Novac C, Engelhard YN, Hazan-Halevy I. The effects of natural antioxidants form tomato extract in treated but uncontrolled hypertensive patients. Cardiovasc. Drugs Ther. 23(2), 145-151 (2009)
157. Reid K, Frank OR, Stocks NP. Dark Chocolate or tomato extract for prehypertension: a randomized controlled trial. BMC Complement. Altern. Med. 9, 22 (2009)
158. Paran E, Engelhard Y. Effect of tomato's lycopene on blood pressure, serum lipoproteins, plasma homocysteine and oxidative stress markers in grade I hypertensive patients. Am. J. Hypertens. 14, 141A (2001)
159. Langsjoen PH, Langsjoen AM. Overview of the use of Co Q 10 in cardiovascular disease. Biofactors 9, 273-284 (1999)
160. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressure and insulin resistance in hypertensive patients with coronary heart disease. J. Hum. Hypertens. 12, 203-208 (1999)
161. Burke BE, Neustenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med. J. 94, 1112-1117 (2001)
162. Rosenfeldt FL, Haas SJ, Krum H, Hadu A. Coenzyme Q 10 in the treatment of hypertension: a meta-analysis of the clinical trials. J. Hum. Hypertens. 21(4), 297-306 (2007)
163. Ankola DD, Viswanas B, Bhardqaj V, Ramarao P, Kumar MN. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplement be used as first line therapeutic agents for prophylaxis/therapy? Eur. J. Pharm. Biopharm. 67(2), 361-369 (2007)
164. McMackin CJ, Widlansky ME, Hambury NM, Haung AL. Effect of combined treatment with alpha lipoic acid and acetyl carnitine on vascular function and blood pressure in patients with coronary artery disease. J. Clin. Hypertens. 9, 249-255 (2007)
165. Salinthone S, Schillace RV, Tsang C, Regan JW, Burdette DN, Carr DW. Lipoic acid stimulates cAMP production via G protein-coupled receptor-dependent and-independent mechanisms. J. Nutr. Biochem. 22(7), 681-690 (2011)
166. Rahman ST, Merchant N, Hague T et al. The impact of lipoic acid on endothelial function and proteinuria in Quinapril-treated diabetic patients with stage I hypertension: results from the Quality Study. J. Cardiovasc. Pharmacol. Ther. 17(2), 139-145 (2012)
167. Huang YD, Li N, Zhang WG et al. The effect of oral alpha-lipoic acid in overweight/obese individuals on the brachial-ankle pulse wave velocity and supine blood pressure: a randomized, crossover, double-blind, placebo-controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi 32(3), 290-296 (2011)
168. Morcos M, Borcea V, Isermann B et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res. Clin. Prac. 52(3), 175-183 (2001)
169. Ying Z, Kherada N, Farrar B et al. Lipioic acid effects on established atherosclerosis. Life Sci. 86, 95-102 (2010)
170. Siani A, Pagano E, Iacone R, Iacoviell L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary l-arginine supplementation in humans. Am. J. Hypertens. 13, 547-551 (2000)
171. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethyl-arginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 20, S60-S62 (1992)
172. Ruiz-Hurtado G, Delgado C. Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors. J. Hypertens. 28(Suppl. 1), S56-S61 (2010)
173. Sonmez A, Celebi G, Erdem G et al. Plasma apelin and ADMA levels in patients with essential hypertension. Clin. Exp. Hypertens. 32(3), 179-183 (2010)
174. Michell DL, Andrews KL, Chin-Dusting JP. Endothelial dysfunction in hypertension: the role of arginase. Front. Biosci. (Schol. Ed.) 3, 946-960 (2011)
175. Rajapakse NW, Mattson DL. Role of l-arginine in nitric oxide production in health and hypertension. Clin. Exp. Pharmacol. Physiol. 36(3), 249-255 (2009)
176. Tsioufis C, Dimitriadis K, Andrikou E et al. ADMA, C-reactive protein and albuminuria in untreated essential hypertension: a cross-sectional study. Am. J. Kidney Dis 55(6), 1050-1059 (2010)
177. Facchinetti F, Saade GR, Neri I, Pizzi C, Longo M, Volpe A. l-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens. Pregnancy 26(1), 121-130 (2007)
178. Neri I, Monari F, Sqarbi L, Berardi A, Masellis G, Facchinetti F. l-arginine supplementation in women with chronic hypertension: impact on blood pressure and maternal and neonatal complications. J. Matern. Fetal Neonatal Med. 23(12), 1456-1460 (2010)
179. Martina V, Masha A, Gigliardi VR et al. Long-term N-acetylcysteine and l-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with Type 2 diabetes. Diabetes Care 31(5), 940-944 (2008)
180. Ast J, Jablecka A, Bogdanski I, Krauss H, Chmara E. Evaluation of the antihypertensive effect of l-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med. Sci. Monit. 16(5), CR266-CR271 (2010)
181. Digiesi V, Cantini F, Bisi G, Guarino G, Brodbeck B. l-carnitine adjuvant therapy in essential hypertension. Clin. Ter. 144, 391-395 (1994)
182. Ghidini O, Azzurro M, Vita G, Sartori G. Evaluation of the therapeutic efficacy of l-carnitine in congestive heart failure. Int. J. Clin. Pharmacol. Ther. Toxicol. 26(4), 217-220 (1988)
183. Digiesi V, Palchetti R, Cantini F. The benefits of l-carnitine therapy in essential arterial hypertension with diabetes mellitus Type II. Minerva Med. 80(3), 227-231 (1989)
184. Huxtable RJ. Physiologic actions of taurine. Physiol Rev. 72, 101-163 (1992)
185. Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation 75, 525-532 (1987)
186. Huxtable RJ, Sebring LA. Cardiovascular actions of taurine. Prog. Clin. Biol. Res. 125, 5-37 (1983)
187. Tanabe Y, Urata H, Kiyonaga A et al. Changes in serum concentrations of taurine and other amino acids in clinical antihypertensive exercise therapy. Clin. Exp. Hypertens. 11, 149-165 (1989)
188. Yamori Y, Taguchi T, Mori H, Mori M. Low cardiovascular risks in the middle age males and femailes excreting greater 24-hour urinary taurine and magnesium in 41 WHO-CARDIAC study populations in the world. J. Biomed. Sci. 17(Suppl. 1), S21-S26 (2010)
189. Hosseini S, Lee J, Sepulveda RT et al. A randomized, double-blind, placebo-controlled, prospective 16 week crossover study to determine the role of pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr. Res. 21, 1251-1260 (2001)
190. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction ofcardiovascular risk factors in subjects with Type 2 diabetes by pycnogenol supplementation. Nutr. Res. 28(5), 315-320 (2008)
191. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol, French maritime pine bark extract improves endothelial function of hypertensive patients. Life Sci. 74(7), 855-862 (2004)
192. Van der Zwan LP, Scheffer PG, Teerlink T. Reduction of myeloperoxidase activity by melatonin and pycnogenol may contribute to their blood pressure lowering effect. Hypertension 56(3), e35 (2010)
193. Cesarone MR, Belcaro G, Stuard S et al. Kidney low and function in hypertension: protective effects of pyconogenol in hypertensive participants-a controlled study. J. Cardiovasc. Pharmacol. Ther. 15(1), 41-46 (2010)
194. Taubert D, Roesen R, Schomig E. Effect of cocoa and tea intake on blood pressure: a meta-analysis. Arch. Intern. Med. 167(7), 626-634 (2007)
195. Grassi D, Lippi C, Necozione S, Desideri G, Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in health persons. Am. J. Clin. Nutr. 81(3), 611-614 (2005)
196. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA 298(1), 49-60 (2007)
197. Cohen DL, Townsend RR. Cocoa ingestion and hypertension-another cup please? J. Clin. Hypertens. 9(8), 647-648 (2007)
198. Reid I, Sullivan T, Fakler P, Frank OR, Stocks NP. Does chocolate reduce blood pressure? A meta-analysis. BMC Med. 8, 39-46 (2010)
199. Egan BM, Laken MA, Donovan JL, Woolson RF. Does dark chocolate have a role in the prevention and management of hypertension?: commentary on the evidence. Hypertension 55(6), 1289-1295 (2010)
200. Desch S, Kobler D, Schmidt J et al. Low vs higher-dose dark chocolate and blood pressure in cardiovascular high-risk patients. Am. J. Hypertens. 23(6), 694-700 (2010)
201. Desch S, Schmidt J, Sonnabend M et al. Effect of cocoa products on blood pressure: systematic review and meta-analysis. Am. J. Hypertens. 23(1), 97-103 (2010)
202. Grassi D, Desideri G, Necozione S et al. Blood pressure is reduced and insulin sensitivity increased in glucose intolerant hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J. Nutr. 138(9), 1671-1676 (2008)
203. Grassi D, Necozione S, Lippi C et al. Cocoa reduces blood pressure and insulin resistance and improved endothelium-dependent vasodilation in hypertensives. Hypertension 46(2), 398-405 (2005)
204. Sankar D, Sambandam G, Ramskrishna Rao M, Pugalendi KV. Modulation of blood pressure, lipid profiles and redox status in hypertensive patients taking different edible oils. Clin. Chim. Acta 355(1-2), 97-104 (2005)
205. Sankar D, Rao MR, Sambandam G, Pugalendi KV. Effect of sesame oil on diuretics or beta-blockers in the modulation of blood pressure, anthropometry, lipid profile and redox status. Yale J. Biol Med. 79(1), 19-26 (2006)
206. Miyawaki T, Aono H, Toyoda-Ono Y, Maeda H, Kiso Y, Moriyama K. Anti-hypertensive effects of sesamin in humans. J. Nutr. Sci. Vitaminol. (Toyko) 55(1), 87-91 (2009)
207. Wichitsranoi J, Weerapreeyakui N, Boonsiri P et al. Antihypertensive and antioxidant effects of dietary black sesame meal in pre-hypertensive humans. Nutr. J. 10(1), 82-88 (2011)
208. Sudhakar B, Kalaiarasi P, Al-Numair KS, Chandramohan G, Rao RK, Pugalendi KV. Effect of combination of edible oils on blood pressure, lipid profile, lipid peroxidative markers, antioxidant status, and electrolytes inpatients with hypertension on nifedipine treatment. Saudi Med. J. 32(4), 379-385 (2011)
209. Sankar D, Rao MR, Sambandam G, Pugalendi KV. A pilot study of open label sesame oil in hypertensive diabetics. J. Med. Food 9(3), 408-412 (2006)
210. Harikumar KB, Sung B, Tharakan ST et al. Sesamin manifests chemopreventive effects through the suppression of NF-kappa-B-regulated cell survival, proliferation, invasion and angiogenic gene products. Mol. Cancer Res. 8(5), 751-761 (2010)
211. Nakano D, Ogura K, Miyakoshi M et al. Antihyptensive effect of angiotensin-I-converting enzyme inhibitory peptides from a sesame protein hydrolysate inspontaneously hypertensive rats. Biosci. Biotechnol. Biochem. 70(5), 1118-1126 (2006)
212. Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43(2), 192-197 (2004)
213. Cavallo A, Daniels SR, Dolan LM, Khoury JC, Bean JA. Blood pressure response to melatonin in type I diabetes. Pediatr. Diabetes 5(1), 26-31 (2004)
214. Cavallo A, Daniels SR, Dolan LM, Bean JA, Khoury JC. Blood pressure-lowering effect of melatonin in Type 1 diabetes. J. Pineal Res. 36(4), 262-266 (2004)
215. Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in Women. Am. J. Hypertens. 18(12 Pt 1), 1614-1618 (2005)
216. Grossman E, Laudon M, Yalcin R et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am. J. Med. 119(10), 898-902 (2006)
217. Rechcinski T, Kurpese M, Trzoa E, Krzeminska-Pakula M. The influence of melatonin supplementation on circadian pattern of blood pressure in patients with coronary artery disease-preliminary report. Pol. Arch. Med. Wewn 115(6), 520-528 (2006)
218. Merkureva GA, Ryzhak GA. Effect of the pineal gland peptide preparation on the diurnal profile of arterial pressure in middle-aged and elderly women with ischemic heart disease and arterial hypertension. Adv. Gerontol. 21(1), 132-142 (2008)
219. Zaslavskaia RM, Scherban EA, Logvinenki SI. Melatonin in combinded therapy of patients with stable angina and arterial hypertension. Klin. Med. (Mosk.) 86, 64-67 (2009)
220. Zamotaev IUN, Enikeev AKH, Kolomets NM. The use of melaxen in combined therapy of arterial hypertension in subjects occupied in assembly line production. Klin. Med. (Mosk.) 87(6), 46-49 (2009)
221. Rechcinski T, Trzos E, Wierzbowski-Drabik K, Krzeminska-Pakute M, Kurpesea M. Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability. Hypertens. Res. 33(1), 56-61 (2002)
222. Kozirog M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile and parameters of oxidative stress in patients with metabolic syndrome. J. Pineal Res. 50(3), 261-266 (2011)
223. Zeman M, Dulkova K, Bada V, Herichova I. Plasma melatonin concentrations in hypertensive patients with the dipping and nondipping blood pressure profile. Life Sci. 75(16), 1795-1803 (2005)
224. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Pressure 12(1), 19-24 (2003)
225. Simko F, Pechanova O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J. Pineal Res. 47(2), 127-133 (2009)
226. Cui HW, Zhang ZX, Gao MT, Liu Y, Su AH, Wang MY. Circadian rhythm of melatonin and blood pressure changes in patients with essential hypertension. Zhonghua Xin Xue Guan Bing Za Zhi 36(1), 20-23 (2008)
227. Ostrowska Z, Kos-Kudla B, Marek B et al. [Circadian rhythm of melatonin in patients with hypertension]. Pol. Merkur. Lekarski 17(97), 50-54 (2004)
228. Shatilo VB, Bondarenke EV, Amtoniuk-Shcheglova IA. Pineal glandmelatonin-producing function in elderly patients with hypertensive disease: age peculiarities. Adv. Gerontol. 23(4), 530-542 (2010)
229. Forman JP, Curhan GC, Schemhammer ES. Urinary melatonin and risk of incident hypertension among young women. J. Hypetens. 28(3), 336-351 (2010)
230. van der Zwan LP, Scheffer PG, Teerlink T. Reduction of myeloperoxidase activity by melatonin and pycnogenol may contribute to their blood pressure lowering effect. Hypertension 56(3), e35 (2010)
231. Li HL, Kang YM, Yu L, Xu HY, Zhao H. Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors. Clin. Exp. Pharmacol. 36(4), 436-440 (2009)
232. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J. Pineal Res. 42(4), 319-322 (2007)
233. Irmak MK, Sizlan A. Essential hypertension seems to result from melatonin-induced epigenetic modifications in area postrema. Med. Hypthesis 66(5), 1000-1007 (2006)
234. De-Leersnyder H, de Biois MC, Vekemans M et al. Beta(1) adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome. J. Med. Genet. 38(9), 586-590 (2011)
235. Watanabe T, Arai Y, Mitsui Y et al. The blood pressure-lowering effect and safety of chlorogenic acid from green coffee bean extract in essential hypertension. Clin. Exp. Hypertens. 28(5), 439-449 (2006)
236. Ochiai R, Jokura H, Suzuki A et al. Green coffee bean extract improve human vasoreactivity. Hypertens. Res. 27(10), 731-737 (2004)
237. Yamaquchi T, Chikama A, Mori K et al. Hydroxyhydroquinone-free coffee: a double-blind, randomizedcontrolled dose-response study of blood pressure. Nutr. Metab. Cardiovasc.Dis 18(6), 408-414 (2008)
238. Chen ZY, Peng C, Jiao R, Wong YM, Yang N, Huang Y. Anti-hypertensive nutraceuticals and functional foods. J. Agric. Food Chem. 57(11), 4485-4499 (2009)
239. Ochiai R, Chikama A, Kataoka K et al. Effects of hydroxyhydroquinone- reduce coffee on vasoreactivity and blood pressure. Hypertens. Res. 32(11), 969-974 (2009)
240. Kozuma K, Tsuchiya S, Kohori J, Hase T, Tokimitsu I. Anti-hypertensive effect of green coffee bean extract on mildly hypertensive subjects. Hypertens. Res. 28(9), 711-718 (2005)
241. Palatini P, Ceolotto G, Ragazzo F et al. CYP 1A2 genotype modifies the association between coffee intake and the risk of hypertension. J. Hypertens. 27(8), 1594-1601 (2008)
242. Hu G, Jousilahti P, Nissinen A, Bidel S, Antiainen R, Tuomilehto J. Coffee consumption and the incidence of antihypertensive drug treatment in Finnish men and women. Am. J. Clin. Nutr. 86(2), 457-464 (2007)
243. Viachopoulos CV, Vyssoulis GG, Alexopoulos NA et al. Effect of chronic coffee consumption on aortic stiffness and wave reflections in hypertensive patients. Eur. J. Clin. Nutr. 61(6), 796-802 (2007)
244. Morand C, Dubray C, Milenkovic D et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am. J. Clin. Nutr. 93(1), 73-80 (2011)
245. Basu A, Penugonda K. Pomegranate juice: a heart-healthy fruit juice. Nutr. Rev. 67(1), 49-56 (2009)
246. Aviram M, Rosenblat M, Gaitine D et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin. Nutr. 23(3), 423-433 (2004)
247. Aviram M, Dornfeld L. Pomegranate juice inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 18(1), 195-198 (2001)
248. Stowe CB. The effects of pomegranate juice consumption on blood pressure and cardiovascular health. Complement. Ther. Clin. Pract. 17(2), 113-115 (2011)
249. Feringa HH, Laskey DA, Dickson JE, Coleman CI. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled tirals. J. Am. Diet Assoc. 111(8), 1173-1181 (2011)
250. Sivaprakasapillai B, Edirsinghe K, Randolph J, Steinberg F, Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism 58(12), 1743-1746 (2009)
251. Edirisinghe I, Burton-Freeman B, Tissa Kappagoda C. Mechanism of the endothelium-dependent relaxation evoked by grape seed extract. Clin. Sci. (Lond.) 114(4), 331-337 (2008)
252. Walker AF, Marakis G, Morris AP, Robinson PA. Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mile essential hypertension. Phytother. Res. 16(1), 48-54 (2002)
253. Walker AF, Marakis G, Simpson E et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomized controlled trial. Br. J. Gen. Pract. 56(527), 437-443 (2006)
254. Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. Am. Fam. Phys. 44(5), 1651-1658 (1991)
255. McCabe BJ, Frankel EH, Wolfe JJ. Handbook of food-drug interactions. CRC Press, Boca Raton, FL, USA (2003)
256. Houston MC. The role of cellular micronutrient analysis and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther. Adv. Cardiovasc. Dis. 4, V165-V183 (2010).